{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:27:53Z","timestamp":1792441673105,"version":"4.5.0"},"reference-count":185,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,24]]},"DOI":"10.7759\/cureus.93123","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T16:43:01Z","timestamp":1758732181000},"source":"Crossref","is-referenced-by-count":5,"title":["A Review of the Recent Advances in the Pharmacological Management of Parkinson\u2019s Disease"],"prefix":"10.7759","author":[{"given":"Allan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanya","family":"Dhami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhakar","family":"Pemminati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228421","article-title":"Neurodegeneration and inflammation\u2014an interesting interplay in Parkinson's disease","volume":"21","author":"Marogianni C","year":"2020","unstructured":"Marogianni C, Sokratous M, Dardiotis E, Hadjigeorgiou GM, Bogdanos D, Xiromerisiou G. Neurodegeneration and inflammation\u2014an interesting interplay in Parkinson's disease. Int J Mol Sci. 2020, 21:16-8. 10.3390\/ijms21228421","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00356","article-title":"Modeling Parkinson's disease with the alpha-synuclein protein","volume":"11","author":"G\u00f3mez-Benito M","year":"2020","unstructured":"G\u00f3mez-Benito M, Granado N, Garc\u00eda-Sanz P, Michel A, Dumoulin M, Moratalla R. Modeling Parkinson's disease with the alpha-synuclein protein. Front Pharmacol. 2020, 11:356. 10.3389\/fphar.2020.00356","journal-title":"Front Pharmacol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094299","article-title":"Roles of the functional interaction between brain cholinergic and dopaminergic systems in the pathogenesis and treatment of schizophrenia and Parkinson's disease","volume":"22","author":"Acharya S","year":"2021","unstructured":"Acharya S, Kim KM. Roles of the functional interaction between brain cholinergic and dopaminergic systems in the pathogenesis and treatment of schizophrenia and Parkinson's disease. Int J Mol Sci. 2021, 22:4-6. 10.3390\/ijms22094299","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-neuro-071013-013916","article-title":"Reassessing models of basal ganglia function and dysfunction","volume":"37","author":"Nelson AB","year":"2014","unstructured":"Nelson AB, Kreitzer AC. Reassessing models of basal ganglia function and dysfunction. Annu Rev Neurosci. 2014, 37:117-35. 10.1146\/annurev-neuro-071013-013916","journal-title":"Annu Rev Neurosci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104700","article-title":"Autonomic dysfunction in Parkinson's disease: implications for pathophysiology, diagnosis, and treatment","volume":"134","author":"Chen Z","year":"2020","unstructured":"Chen Z, Li G, Liu J. Autonomic dysfunction in Parkinson's disease: implications for pathophysiology, diagnosis, and treatment. Neurobiol Dis. 2020, 134:104700. 10.1016\/j.nbd.2019.104700","journal-title":"Neurobiol Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-181474","article-title":"The emerging evidence of the Parkinson pandemic","volume":"8","author":"Dorsey ER","year":"2018","unstructured":"Dorsey ER, Sherer T, Okun MS, Bloem BR. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis. 2018, 8:S3-8. 10.3233\/JPD-181474","journal-title":"J Parkinsons Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00788-4","article-title":"Rotigotine transdermal patch for motor and non-motor Parkinson's disease: a review of 12 years' clinical experience","volume":"35","author":"Raeder V","year":"2021","unstructured":"Raeder V, Boura I, Leta V, et al.. Rotigotine transdermal patch for motor and non-motor Parkinson's disease: a review of 12 years' clinical experience. CNS Drugs. 2021, 35:215-31. 10.1007\/s40263-020-00788-4","journal-title":"CNS Drugs"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-018-0162-2","article-title":"NMDA antagonists for treating the non-motor symptoms in Parkinson's disease","volume":"8","author":"Vanle B","year":"2018","unstructured":"Vanle B, Olcott W, Jimenez J, Bashmi L, Danovitch I, IsHak WW. NMDA antagonists for treating the non-motor symptoms in Parkinson's disease. Transl Psychiatry. 2018, 8:117. 10.1038\/s41398-018-0162-2","journal-title":"Transl Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref10","article-title":"Parkinson's disease and its management: part 1: disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis","volume":"40","author":"DeMaagd G","year":"2015","unstructured":"DeMaagd G, Philip A. Parkinson's disease and its management: part 1: disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. P T. 2015, 40:504-32.","journal-title":"P T"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-130186","article-title":"Levodopa in the treatment of Parkinson's disease: current status and new developments","volume":"3","author":"Salat D","year":"2013","unstructured":"Salat D, Tolosa E. Levodopa in the treatment of Parkinson's disease: current status and new developments. J Parkinsons Dis. 2013, 3:255-69. 10.3233\/JPD-130186","journal-title":"J Parkinsons Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2016.12.004","article-title":"Apomorphine and levodopa in Parkinson's disease: two revolutionary drugs from the 1950s","volume":"33","author":"Djamshidian A","year":"2016","unstructured":"Djamshidian A, Poewe W. Apomorphine and levodopa in Parkinson's disease: two revolutionary drugs from the 1950s. Parkinsonism Relat Disord. 2016, 33:S9-S12. 10.1016\/j.parkreldis.2016.12.004","journal-title":"Parkinsonism Relat Disord"},{"key":"ref13","article-title":"Dopamine","author":"Sonne J","year":"2023","unstructured":"Sonne J, Goyal A, Lopez-Ojeda W. Dopamine. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref14","article-title":"Dopamine Agonists","author":"Choi J","year":"2023","unstructured":"Choi J, Horner KA. Dopamine Agonists. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/ph14080717","article-title":"Current therapies in clinical trials of Parkinson's disease: a 2021 update","volume":"14","author":"Prasad EM","year":"2021","unstructured":"Prasad EM, Hung SY. Current therapies in clinical trials of Parkinson's disease: a 2021 update. Pharmaceuticals (Basel). 2021, 14:26-8. 10.3390\/ph14080717","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2174\/138920021705160324170558","article-title":"Parkinson's disease: recent updates in the identification of human DOPA decarboxylase inhibitors","volume":"17","author":"Montioli R","year":"2016","unstructured":"Montioli R, Voltattorni CB, Bertoldi M. Parkinson's disease: recent updates in the identification of human DOPA decarboxylase inhibitors. Curr Drug Metab. 2016, 17:513-8. 10.2174\/138920021705160324170558","journal-title":"Curr Drug Metab"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1159\/000215875","article-title":"Levodopa: past, present, and future","volume":"62","author":"Hauser RA","year":"2009","unstructured":"Hauser RA. Levodopa: past, present, and future. Eur Neurol. 2009, 62:1-8. 10.1159\/000215875","journal-title":"Eur Neurol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-023-00478-y","article-title":"DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease","volume":"3","author":"Pereira JB","year":"2023","unstructured":"Pereira JB, Kumar A, Hall S, et al.. DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease. Nat Aging. 2023, 3:1201-9. 10.1038\/s43587-023-00478-y","journal-title":"Nat Aging"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.2019","article-title":"Association of Parkinson's disease to Parkinson's plus syndromes, Lewy body dementia, and Alzheimer's dementia","volume":"7","author":"Prajjwal P","year":"2024","unstructured":"Prajjwal P, Kolanu ND, Reddy YB, et al.. Association of Parkinson's disease to Parkinson's plus syndromes, Lewy body dementia, and Alzheimer's dementia. Health Sci Rep. 2024, 7:e2019. 10.1002\/hsr2.2019","journal-title":"Health Sci Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007173","article-title":"Increased dose of carbidopa with levodopa and entacapone improves \"off\" time in a randomized trial","volume":"92","author":"Trenkwalder C","year":"2019","unstructured":"Trenkwalder C, Kuoppam\u00e4ki M, Vahteristo M, M\u00fcller T, Ellm\u00e9n J. Increased dose of carbidopa with levodopa and entacapone improves \"off\" time in a randomized trial. Neurology. 2019, 92:e1487-96. 10.1212\/WNL.0000000000007173","journal-title":"Neurology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/mds.24998","article-title":"Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease","volume":"27","author":"Brod LS","year":"2012","unstructured":"Brod LS, Aldred JL, Nutt JG. Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease. Mov Disord. 2012, 27:750-3. 10.1002\/mds.24998","journal-title":"Mov Disord"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01747-1","article-title":"The long-term impact of levodopa\/carbidopa intestinal gel on \u2018off\u2019-time in patients with advanced Parkinson\u2019s disease: a systematic review","volume":"38","author":"Antonini A","year":"2021","unstructured":"Antonini A, Odin P, Pahwa R, et al.. The long-term impact of levodopa\/carbidopa intestinal gel on \u2018off\u2019-time in patients with advanced Parkinson\u2019s disease: a systematic review. Adv Ther. 2021, 38:2854-90. 10.1007\/s12325-021-01747-1","journal-title":"Adv Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/ncn3.152","article-title":"Pharmacokinetics of levodopa\/benserazide versus levodopa\/carbidopa in healthy subjects and patients with Parkinson's disease","volume":"2","author":"Iwaki H","year":"2015","unstructured":"Iwaki H, Nishikawa N, Nagai M, et al.. Pharmacokinetics of levodopa\/benserazide versus levodopa\/carbidopa in healthy subjects and patients with Parkinson's disease. Neurol Clin Neurosci. 2015, 2:152. 10.1111\/ncn3.152","journal-title":"Neurol Clin Neurosci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-015-1449-6","article-title":"Efficacy and safety of entacapone in levodopa\/carbidopa versus levodopa\/benserazide treated Parkinson's disease patients with wearing-off","volume":"122","author":"Kuoppam\u00e4ki M","year":"2015","unstructured":"Kuoppam\u00e4ki M, Leinonen M, Poewe W. Efficacy and safety of entacapone in levodopa\/carbidopa versus levodopa\/benserazide treated Parkinson's disease patients with wearing-off. J Neural Transm (Vienna). 2015, 122:1709-14. 10.1007\/s00702-015-1449-6","journal-title":"J Neural Transm (Vienna)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120263","article-title":"The relationship between the distinct ratios of benserazide and carbidopa to levodopa and motor complications in Parkinson's disease: a retrospective cohort study","volume":"437","author":"Baba Y","year":"2022","unstructured":"Baba Y, Futamura A, Kinno R, et al.. The relationship between the distinct ratios of benserazide and carbidopa to levodopa and motor complications in Parkinson's disease: a retrospective cohort study. J Neurol Sci. 2022, 437:120263. 10.1016\/j.jns.2022.120263","journal-title":"J Neurol Sci"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2147\/ppa.s4084","article-title":"Levodopa\/carbidopa and entacapone in the treatment of Parkinson's disease: efficacy, safety and patient preference","volume":"3","author":"M\u00fcller T","year":"2009","unstructured":"M\u00fcller T. Levodopa\/carbidopa and entacapone in the treatment of Parkinson's disease: efficacy, safety and patient preference. Patient Prefer Adherence. 2009, 3:51-9. 10.2147\/ppa.s4084","journal-title":"Patient Prefer Adherence"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-006-0442-5","article-title":"Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa\/carbidopa with and without entacapone in patients with Parkinson's disease","volume":"113","author":"M\u00fcller T","year":"2006","unstructured":"M\u00fcller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, Goetze O, Woitalla D. Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa\/carbidopa with and without entacapone in patients with Parkinson's disease. J Neural Transm (Vienna). 2006, 113:1441-8. 10.1007\/s00702-006-0442-5","journal-title":"J Neural Transm (Vienna)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.61.10.1563","article-title":"Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease","volume":"61","author":"Olanow CW","year":"2004","unstructured":"Olanow CW, Kieburtz K, Stern M, Watts R, Langston JW, Guarnieri M, Hubble J. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol. 2004, 61:1563-8. 10.1001\/archneur.61.10.1563","journal-title":"Arch Neurol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-020-04303-x","article-title":"Levodopa\/carbidopa\/entacapone for the treatment of early Parkinson's disease: a meta-analysis","volume":"41","author":"Liao X","year":"2020","unstructured":"Liao X, Wu N, Liu D, Shuai B, Li S, Li K. Levodopa\/carbidopa\/entacapone for the treatment of early Parkinson's disease: a meta-analysis. Neurol Sci. 2020, 41:2045-54. 10.1007\/s10072-020-04303-x","journal-title":"Neurol Sci"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.4.1.69","article-title":"Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy","volume":"4","author":"Borges N","year":"2005","unstructured":"Borges N. Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy. Expert Opin Drug Saf. 2005, 4:69-73. 10.1517\/14740338.4.1.69","journal-title":"Expert Opin Drug Saf"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200059060-00004","article-title":"Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease","volume":"59","author":"Kaakkola S","year":"2000","unstructured":"Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs. 2000, 59:1233-50. 10.2165\/00003495-200059060-00004","journal-title":"Drugs"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2007.00035.x","article-title":"Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease","volume":"14","author":"Lees AJ","year":"2008","unstructured":"Lees AJ. Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease. CNS Neurosci Ther. 2008, 14:83-93. 10.1111\/j.1527-3458.2007.00035.x","journal-title":"CNS Neurosci Ther"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.042846","article-title":"Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat","volume":"304","author":"Forsberg M","year":"2003","unstructured":"Forsberg M, Lehtonen M, Heikkinen M, Savolainen J, J\u00e4rvinen T, M\u00e4nnist\u00f6 PT. Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. J Pharmacol Exp Ther. 2003, 304:498-506. 10.1124\/jpet.102.042846","journal-title":"J Pharmacol Exp Ther"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-020-03081-x","article-title":"Safety and efficacy of tolcapone in Parkinson's disease: systematic review","volume":"77","author":"Artusi CA","year":"2021","unstructured":"Artusi CA, Sarro L, Imbalzano G, Fabbri M, Lopiano L. Safety and efficacy of tolcapone in Parkinson's disease: systematic review. Eur J Clin Pharmacol. 2021, 77:817-29. 10.1007\/s00228-020-03081-x","journal-title":"Eur J Clin Pharmacol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02697.x","article-title":"Levodopa in the treatment of Parkinson's disease","volume":"16","author":"Schapira AH","year":"2009","unstructured":"Schapira AH, Emre M, Jenner P, Poewe W. Levodopa in the treatment of Parkinson's disease. Eur J Neurol. 2009, 16:982-9. 10.1111\/j.1468-1331.2009.02697.x","journal-title":"Eur J Neurol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-016-2142-x","article-title":"Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson's disease","volume":"73","author":"Montastruc F","year":"2017","unstructured":"Montastruc F, Moulis F, Araujo M, Chebane L, Rascol O, Montastruc JL. Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson's disease. Eur J Clin Pharmacol. 2017, 73:99-103. 10.1007\/s00228-016-2142-x","journal-title":"Eur J Clin Pharmacol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrl.2011.04.012","article-title":"Dopaminergic agonists in Parkinson's disease","volume":"29","author":"Alonso C\u00e1novas A","year":"2014","unstructured":"Alonso C\u00e1novas A, Luquin Piudo R, Garc\u00eda Ruiz-Espiga P, et al.. Dopaminergic agonists in Parkinson's disease. Neurologia. 2014, 29:230-41. 10.1016\/j.nrl.2011.04.012","journal-title":"Neurologia"},{"key":"ref38","article-title":"Side effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacology","volume":"89","author":"Borovac JA","year":"2016","unstructured":"Borovac JA. Side effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacology. Yale J Biol Med. 2016, 89:37-47.","journal-title":"Yale J Biol Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/S1353-8020(09)70835-1","article-title":"Role of dopamine receptor agonists in the treatment of early Parkinson's disease","volume":"15","author":"Bonuccelli U","year":"2009","unstructured":"Bonuccelli U, Del Dotto P, Rascol O. Role of dopamine receptor agonists in the treatment of early Parkinson's disease. Parkinsonism Relat Disord. 2009, 15:44-53. 10.1016\/S1353-8020(09)70835-1","journal-title":"Parkinsonism Relat Disord"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001203","article-title":"Bromocriptine for levodopa-induced motor complications in Parkinson's disease","volume":"1998","author":"van Hilten JJ","year":"2000","unstructured":"van Hilten JJ, Ramaker C, Van de Beek WJ, Finken MJ. Bromocriptine for levodopa-induced motor complications in Parkinson's disease. Cochrane Database Syst Rev. 2000, 1998:CD001203. 10.1002\/14651858.CD001203","journal-title":"Cochrane Database Syst Rev"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175884","article-title":"Dopamine agonists versus levodopa monotherapy in early Parkinson's disease for the potential risks of motor complications: a network meta-analysis","volume":"954","author":"Zhang Q","year":"2023","unstructured":"Zhang Q, Chen X, Chen F, Wen S, Zhou C. Dopamine agonists versus levodopa monotherapy in early Parkinson's disease for the potential risks of motor complications: a network meta-analysis. Eur J Pharmacol. 2023, 954:175884. 10.1016\/j.ejphar.2023.175884","journal-title":"Eur J Pharmacol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22385","article-title":"Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists","volume":"24","author":"Andersohn F","year":"2009","unstructured":"Andersohn F, Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. Mov Disord. 2009, 24:129-33. 10.1002\/mds.22385","journal-title":"Mov Disord"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2010.11.013","article-title":"Neuroleptic malignant syndrome associated with bromocriptine withdrawal in Parkinson's disease--a case report","volume":"33","author":"Wu YF","year":"2011","unstructured":"Wu YF, Kan YS, Yang CH. Neuroleptic malignant syndrome associated with bromocriptine withdrawal in Parkinson's disease--a case report. Gen Hosp Psychiatry. 2011, 33:301.e7-8. 10.1016\/j.genhosppsych.2010.11.013","journal-title":"Gen Hosp Psychiatry"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.3.10.1481","article-title":"Use of the dopamine agonist cabergoline in the treatment of movement disorders","volume":"3","author":"Marco AD","year":"2002","unstructured":"Marco AD, Appiah-Kubi LS, Chaudhuri KR. Use of the dopamine agonist cabergoline in the treatment of movement disorders. Expert Opin Pharmacother. 2002, 3:1481-7. 10.1517\/14656566.3.10.1481","journal-title":"Expert Opin Pharmacother"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1590\/0004-282X-ANP-2021-0219","article-title":"Guidelines for Parkinson's disease treatment: consensus from the Movement Disorders Scientific Department of the Brazilian Academy of Neurology - motor symptoms","volume":"80","author":"Saba RA","year":"2022","unstructured":"Saba RA, Maia DP, Cardoso FE, et al.. Guidelines for Parkinson's disease treatment: consensus from the Movement Disorders Scientific Department of the Brazilian Academy of Neurology - motor symptoms. Arq Neuropsiquiatr. 2022, 80:316-29. 10.1590\/0004-282X-ANP-2021-0219","journal-title":"Arq Neuropsiquiatr"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.18926\/AMO\/48266","article-title":"Long-term effects of cabergoline and levodopa in Japanese patients with early Parkinson's disease: a 5-year prospective study","volume":"66","author":"Utsumi H","year":"2012","unstructured":"Utsumi H. Long-term effects of cabergoline and levodopa in Japanese patients with early Parkinson's disease: a 5-year prospective study. Acta Med Okayama. 2012, 66:163-70. 10.18926\/AMO\/48266","journal-title":"Acta Med Okayama"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-56015-1_223-1","article-title":"Cabergoline in the treatment of Parkinson\u2019s disease","author":"Tsuboi T","year":"2019","unstructured":"Tsuboi T, Watanabe H, Katsuno M, Sobue G. Cabergoline in the treatment of Parkinson\u2019s disease. NeuroPsychopharmacotherapy. Riederer P, Laux G, Mulsant B, Le W, Nagatsu T (ed): Springer, Cham, Switzerland; 2019. 4:1-10. 10.1007\/978-3-319-56015-1_223-1"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-56015-1_287-1","article-title":"Lisuride: an 8-alpha-ergoline with ergot antagonistic properties","author":"Horowski R","year":"2021","unstructured":"Horowski R. Lisuride: an 8-alpha-ergoline with ergot antagonistic properties. NeuroPsychopharmacotherapy. Riederer P, Laux G, Nagatsu T. and W, Le and Cham, Riederer C (ed): Springer, Cham, Switzerland; 2021. 4:44-6. 10.1007\/978-3-319-56015-1_287-1"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awf214","article-title":"Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease","volume":"125","author":"Stocchi F","year":"2002","unstructured":"Stocchi F, Ruggieri S, Vacca L, Olanow CW. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain. 2002, 125:2058-66. 10.1093\/brain\/awf214","journal-title":"Brain"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1159\/000008188","article-title":"Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. The French Lisuride Study Group","volume":"44","author":"Allain H","year":"2000","unstructured":"Allain H, Dest\u00e9e A, Petit H, Patay M, Sch\u00fcck S, Bentu\u00e9-Ferrer D, Le Cavorzin P. Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. The French Lisuride Study Group. Eur Neurol. 2000, 44:22-30. 10.1159\/000008188","journal-title":"Eur Neurol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200603000-00005","article-title":"Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis","volume":"29","author":"Hofmann C","year":"2006","unstructured":"Hofmann C, Penner U, Dorow R, et al.. Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Clin Neuropharmacol. 2006, 29:80-6. 10.1097\/00002826-200603000-00005","journal-title":"Clin Neuropharmacol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2009.06.029","article-title":"Antidepressant effects of pramipexole, a dopamine D3\/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats","volume":"616","author":"Breuer ME","year":"2009","unstructured":"Breuer ME, Groenink L, Oosting RS, Buerger E, Korte M, Ferger B, Olivier B. Antidepressant effects of pramipexole, a dopamine D3\/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats. Eur J Pharmacol. 2009, 616:134-40. 10.1016\/j.ejphar.2009.06.029","journal-title":"Eur J Pharmacol"},{"key":"ref53","article-title":"Pramipexole","author":"Singh R","year":"2024","unstructured":"Singh R, Parmar M. Pramipexole. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.2165\/11585090-000000000-00000","article-title":"Role of pramipexole in the management of Parkinson's disease","volume":"24","author":"Antonini A","year":"2010","unstructured":"Antonini A, Barone P, Ceravolo R, Fabbrini G, Tinazzi M, Abbruzzese G. Role of pramipexole in the management of Parkinson's disease. CNS Drugs. 2010, 24:829-41. 10.2165\/11585090-000000000-00000","journal-title":"CNS Drugs"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.2165\/11204570-000000000-00000","article-title":"Pramipexole extended release in Parkinson's disease","volume":"24","author":"Chwieduk CM","year":"2010","unstructured":"Chwieduk CM, Curran MP. Pramipexole extended release in Parkinson's disease. CNS Drugs. 2010, 24:327-36. 10.2165\/11204570-000000000-00000","journal-title":"CNS Drugs"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200326060-00005","article-title":"Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis","volume":"26","author":"Etminan M","year":"2003","unstructured":"Etminan M, Gill S, Samii A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis. Drug Saf. 2003, 26:439-44. 10.2165\/00002018-200326060-00005","journal-title":"Drug Saf"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200060010-00007","article-title":"Ropinirole: a review of its use in the management of Parkinson's disease","volume":"60","author":"Matheson AJ","year":"2000","unstructured":"Matheson AJ, Spencer CM. Ropinirole: a review of its use in the management of Parkinson's disease. Drugs. 2000, 60:115-37. 10.2165\/00003495-200060010-00007","journal-title":"Drugs"},{"key":"ref58","article-title":"Ropinirole","author":"Rewane A","year":"2024","unstructured":"Rewane A, Patel P, Nagalli S. Ropinirole. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref59","article-title":"Update on ropinirole in the treatment of Parkinson's disease","volume":"5","author":"Shill HA","year":"2009","unstructured":"Shill HA, Stacy M. Update on ropinirole in the treatment of Parkinson's disease. Neuropsychiatr Dis Treat. 2009, 5:33-6.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28071","article-title":"Ropinirole patch versus placebo, ropinirole extended-release tablet in advanced Parkinson's disease","volume":"35","author":"Hattori N","year":"2020","unstructured":"Hattori N, Mochizuki H, Hasegawa K, et al.. Ropinirole patch versus placebo, ropinirole extended-release tablet in advanced Parkinson's disease. Mov Disord. 2020, 35:1565-73. 10.1002\/mds.28071","journal-title":"Mov Disord"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12508","article-title":"Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome","volume":"1329","author":"Benitez A","year":"2014","unstructured":"Benitez A, Edens H, Fishman J, Moran K, Asgharnejad M. Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome. Ann N Y Acad Sci. 2014, 1329:45-66. 10.1111\/nyas.12508","journal-title":"Ann N Y Acad Sci"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-019-00646-y","article-title":"Rotigotine transdermal patch: a review in Parkinson's disease","volume":"33","author":"Frampton JE","year":"2019","unstructured":"Frampton JE. Rotigotine transdermal patch: a review in Parkinson's disease. CNS Drugs. 2019, 33:707-18. 10.1007\/s40263-019-00646-y","journal-title":"CNS Drugs"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069738","article-title":"Rotigotine transdermal patch in Parkinson's disease: a systematic review and meta-analysis","volume":"8","author":"Zhou CQ","year":"2013","unstructured":"Zhou CQ, Li SS, Chen ZM, Li FQ, Lei P, Peng GG. Rotigotine transdermal patch in Parkinson's disease: a systematic review and meta-analysis. PLoS One. 2013, 8:e69738. 10.1371\/journal.pone.0069738","journal-title":"PLoS One"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252355.79284.22","article-title":"Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease","volume":"68","author":"Watts RL","year":"2007","unstructured":"Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007, 68:272-6. 10.1212\/01.wnl.0000252355.79284.22","journal-title":"Neurology"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2016.04.022","article-title":"Rotigotine transdermal patch in Chinese patients with early Parkinson's disease: a randomized, double-blind, placebo-controlled pivotal study","volume":"28","author":"Zhang ZX","year":"2016","unstructured":"Zhang ZX, Shang HF, Hu X, et al.. Rotigotine transdermal patch in Chinese patients with early Parkinson's disease: a randomized, double-blind, placebo-controlled pivotal study. Parkinsonism Relat Disord. 2016, 28:49-55. 10.1016\/j.parkreldis.2016.04.022","journal-title":"Parkinsonism Relat Disord"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0b013e318278be9b","article-title":"Impulse control disorders and compulsive behaviors associated with dopaminergic therapies in Parkinson disease","volume":"2","author":"Weiss HD","year":"2012","unstructured":"Weiss HD, Marsh L. Impulse control disorders and compulsive behaviors associated with dopaminergic therapies in Parkinson disease. Neurol Clin Pract. 2012, 2:267-74. 10.1212\/CPJ.0b013e318278be9b","journal-title":"Neurol Clin Pract"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-212976","article-title":"Monoamine oxidase-B inhibitors for the treatment of Parkinson's disease: past, present, and future","volume":"12","author":"Tan YY","year":"2022","unstructured":"Tan YY, Jenner P, Chen SD. Monoamine oxidase-B inhibitors for the treatment of Parkinson's disease: past, present, and future. J Parkinsons Dis. 2022, 12:477-93. 10.3233\/JPD-212976","journal-title":"J Parkinsons Dis"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.8940-21","article-title":"Recent advances in drug therapy for Parkinson's disease","volume":"62","author":"Murakami H","year":"2023","unstructured":"Murakami H, Shiraishi T, Umehara T, Omoto S, Iguchi Y. Recent advances in drug therapy for Parkinson's disease. Intern Med. 2023, 62:33-42. 10.2169\/internalmedicine.8940-21","journal-title":"Intern Med"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1097\/00131746-200407000-00005","article-title":"The role of monoamine oxidase inhibitors in current psychiatric practice","volume":"10","author":"Fiedorowicz JG","year":"2004","unstructured":"Fiedorowicz JG, Swartz KL. The role of monoamine oxidase inhibitors in current psychiatric practice. J Psychiatr Pract. 2004, 10:239-48. 10.1097\/00131746-200407000-00005","journal-title":"J Psychiatr Pract"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.52965\/001c.39576","article-title":"Clinically relevant drug interactions with monoamine oxidase inhibitors","volume":"10","author":"Edinoff AN","year":"2022","unstructured":"Edinoff AN, Swinford CR, Odisho AS, et al.. Clinically relevant drug interactions with monoamine oxidase inhibitors. Health Psychol Res. 2022, 10:39576. 10.52965\/001c.39576","journal-title":"Health Psychol Res"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-020-00924-4","article-title":"Pharmacological treatment of early motor manifestations of Parkinson disease (PD)","volume":"17","author":"Sy MA","year":"2020","unstructured":"Sy MA, Fernandez HH.  Pharmacological treatment of early motor manifestations of Parkinson disease (PD). Neurotherapeutics. 2020, 17:1331-8. 10.1007\/s13311-020-00924-4","journal-title":"Neurotherapeutics"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000239","article-title":"A randomized double-blind placebo-controlled phase III trial of selegiline monotherapy for early Parkinson disease","volume":"40","author":"Mizuno Y","year":"2017","unstructured":"Mizuno Y, Hattori N, Kondo T, et al.. A randomized double-blind placebo-controlled phase III trial of selegiline monotherapy for early Parkinson disease. Clin Neuropharmacol. 2017, 40:201-7. 10.1097\/WNF.0000000000000239","journal-title":"Clin Neuropharmacol"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0b013e3283542fc2","article-title":"Therapies in Parkinson's disease","volume":"25","author":"Jankovic J","year":"2012","unstructured":"Jankovic J, Poewe W. Therapies in Parkinson's disease. Curr Opin Neurol. 2012, 25:433-47. 10.1097\/WCO.0b013e3283542fc2","journal-title":"Curr Opin Neurol"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2008.09.009","article-title":"Targets for neuroprotection in Parkinson's disease","volume":"1792","author":"Yacoubian TA","year":"2009","unstructured":"Yacoubian TA, Standaert DG. Targets for neuroprotection in Parkinson's disease. Biochim Biophys Acta. 2009, 1792:676-87. 10.1016\/j.bbadis.2008.09.009","journal-title":"Biochim Biophys Acta"},{"key":"ref75","article-title":"Selegiline","author":"Moore JJ","year":"2025","unstructured":"Moore JJ, Saadabadi A. Selegiline. StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20145","article-title":"Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients","volume":"19","author":"Stern MB","year":"2004","unstructured":"Stern MB, Marek KL, Friedman J, Hauser RA, LeWitt PA, Tarsy D, Olanow CW. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Mov Disord. 2004, 19:916-23. 10.1002\/mds.20145","journal-title":"Mov Disord"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809335","article-title":"A double-blind, delayed-start trial of rasagiline in Parkinson's disease","volume":"361","author":"Olanow CW","year":"2009","unstructured":"Olanow CW, Rascol O, Hauser R, et al.. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009, 361:1268-78. 10.1056\/NEJMoa0809335","journal-title":"N Engl J Med"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000167","article-title":"Comparison of selegiline and rasagiline therapies in Parkinson disease: a real-life study","volume":"39","author":"Peretz C","year":"2016","unstructured":"Peretz C, Segev H, Rozani V, Gurevich T, El-Ad B, Tsamir J, Giladi N. Comparison of selegiline and rasagiline therapies in Parkinson disease: a real-life study. Clin Neuropharmacol. 2016, 39:227-31. 10.1097\/WNF.0000000000000167","journal-title":"Clin Neuropharmacol"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.5607\/en.2011.20.1.1","article-title":"MAO-inhibitors in Parkinson's disease","volume":"20","author":"Riederer P","year":"2011","unstructured":"Riederer P, Laux G. MAO-inhibitors in Parkinson's disease. Exp Neurobiol. 2011, 20:1-17. 10.5607\/en.2011.20.1.1","journal-title":"Exp Neurobiol"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1016\/j.baga.2012.06.003","article-title":"Drug interactions with selegiline versus rasagiline","volume":"2","author":"Csoti I","year":"2012","unstructured":"Csoti I, Storch A, M\u00fcller W, Jost WH. Drug interactions with selegiline versus rasagiline. Basal Ganglia. 2012, 2:4. 10.1016\/j.baga.2012.06.003","journal-title":"Basal Ganglia"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S139545","article-title":"Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: a review of the current clinical evidence","volume":"14","author":"Bette S","year":"2018","unstructured":"Bette S, Shpiner DS, Singer C, Moore H. Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: a review of the current clinical evidence. Ther Clin Risk Manag. 2018, 14:1737-45. 10.2147\/TCRM.S139545","journal-title":"Ther Clin Risk Manag"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2018.01.033","article-title":"Safinamide: a new hope for Parkinson's disease?","volume":"23","author":"Teixeira FG","year":"2018","unstructured":"Teixeira FG, Gago MF, Marques P, Moreira PS, Magalh\u00e3es R, Sousa N, Salgado AJ. Safinamide: a new hope for Parkinson's disease?. Drug Discov Today. 2018, 23:736-44. 10.1016\/j.drudis.2018.01.033","journal-title":"Drug Discov Today"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.2217\/nmt-2020-0017","article-title":"Safinamide in the treatment of Parkinson's disease","volume":"10","author":"M\u00fcller T","year":"2020","unstructured":"M\u00fcller T. Safinamide in the treatment of Parkinson's disease. Neurodegener Dis Manag. 2020, 10:195-204. 10.2217\/nmt-2020-0017","journal-title":"Neurodegener Dis Manag"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25961","article-title":"Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease","volume":"29","author":"Borgohain R","year":"2014","unstructured":"Borgohain R, Szasz J, Stanzione P, et al.. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease. Mov Disord. 2014, 29:1273-80. 10.1002\/mds.25961","journal-title":"Mov Disord"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25751","article-title":"Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations","volume":"29","author":"Borgohain R","year":"2014","unstructured":"Borgohain R, Szasz J, Stanzione P, et al.. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. Mov Disord. 2014, 29:229-37. 10.1002\/mds.25751","journal-title":"Mov Disord"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-191765","article-title":"Long-term efficacy of safinamide on symptoms severity and quality of life in fluctuating Parkinson's disease patients","volume":"10","author":"Cattaneo C","year":"2020","unstructured":"Cattaneo C, Jost WH, Bonizzoni E. Long-term efficacy of safinamide on symptoms severity and quality of life in fluctuating Parkinson's disease patients. J Parkinsons Dis. 2020, 10:89-97. 10.3233\/JPD-191765","journal-title":"J Parkinsons Dis"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.13347","article-title":"Antimuscarinic anticholinergic medications in Parkinson disease: to prescribe or deprescribe?","volume":"8","author":"Barrett MJ","year":"2021","unstructured":"Barrett MJ, Sargent L, Nawaz H, Weintraub D, Price ET, Willis AW. Antimuscarinic anticholinergic medications in Parkinson disease: to prescribe or deprescribe?. Mov Disord Clin Pract. 2021, 8:1181-8. 10.1002\/mdc3.13347","journal-title":"Mov Disord Clin Pract"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-225060","article-title":"Pharmacological treatment of tremor in Parkinson's disease revisited","volume":"13","author":"Pirker W","year":"2023","unstructured":"Pirker W, Katzenschlager R, Hallett M, Poewe W. Pharmacological treatment of tremor in Parkinson's disease revisited. J Parkinsons Dis. 2023, 13:127-44. 10.3233\/JPD-225060","journal-title":"J Parkinsons Dis"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-212769","article-title":"Anticholinergic medication burden in Parkinson's disease outpatients","volume":"12","author":"Nawaz H","year":"2022","unstructured":"Nawaz H, Sargent L, Quilon H, et al.. Anticholinergic medication burden in Parkinson's disease outpatients. J Parkinsons Dis. 2022, 12:599-606. 10.3233\/JPD-212769","journal-title":"J Parkinsons Dis"},{"key":"ref90","article-title":"Trihexyphenidyl","author":"Jilani TN","year":"2025","unstructured":"Jilani TN, Sabir S, Patel P, Sharma S. Trihexyphenidyl. StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000020129","article-title":"Trihexyphenidyl-induced malignant hyperthermia in a patient with Parkinson's disease complicated with pneumonia: a case report","volume":"99","author":"Zhao J","year":"2020","unstructured":"Zhao J, Xu G, Feng C, Chen Y, Kang Y, Liu F, Ma W. Trihexyphenidyl-induced malignant hyperthermia in a patient with Parkinson's disease complicated with pneumonia: a case report. Medicine (Baltimore). 2020, 99:e20129. 10.1097\/MD.0000000000020129","journal-title":"Medicine (Baltimore)"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.3390\/antiox13010026","article-title":"Trihexyphenidyl alters its host's metabolism, neurobehavioral patterns, and gut microbiome feedback loop\u2014the modulating role of Anacyclus pyrethrum","volume":"13","author":"Baslam A","year":"2023","unstructured":"Baslam A, Azraida H, Aboufatima R, et al.. Trihexyphenidyl alters its host's metabolism, neurobehavioral patterns, and gut microbiome feedback loop\u2014the modulating role of Anacyclus pyrethrum. Antioxidants (Basel). 2023, 13:23-5. 10.3390\/antiox13010026","journal-title":"Antioxidants (Basel)"},{"key":"ref93","article-title":"Benztropine","author":"Ahuja A","year":"2025","unstructured":"Ahuja A, Patel P, Abdijadid S. Benztropine. StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-018-0105-0","article-title":"Antipsychotic-related movement disorders: drug-induced parkinsonism vs. tardive dyskinesia\u2014key differences in pathophysiology and clinical management","volume":"7","author":"Ward KM","year":"2018","unstructured":"Ward KM, Citrome L. Antipsychotic-related movement disorders: drug-induced parkinsonism vs. tardive dyskinesia\u2014key differences in pathophysiology and clinical management. Neurol Ther. 2018, 7:233-48. 10.1007\/s40120-018-0105-0","journal-title":"Neurol Ther"},{"key":"ref95","article-title":"Withdrawal-emergent dyskinesia related to benztropine: a case report","volume":"122","author":"Thalner S","year":"2023","unstructured":"Thalner S, Agrawal H. Withdrawal-emergent dyskinesia related to benztropine: a case report. WMJ. 2023, 122:143-5.","journal-title":"WMJ"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-7321-7_1","article-title":"NMDA receptors in the central nervous system","volume":"1677","author":"Hansen KB","year":"2017","unstructured":"Hansen KB, Yi F, Perszyk RE, Menniti FS, Traynelis SF. NMDA receptors in the central nervous system. Methods Mol Biol. 2017, 1677:1-80. 10.1007\/978-1-4939-7321-7_1","journal-title":"Methods Mol Biol"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2015.00245","article-title":"NMDA receptor GluN2A\/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients","volume":"9","author":"Mellone M","year":"2015","unstructured":"Mellone M, Stanic J, Hernandez LF, et al.. NMDA receptor GluN2A\/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients. Front Cell Neurosci. 2015, 9:245. 10.3389\/fncel.2015.00245","journal-title":"Front Cell Neurosci"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.3390\/ph16111535","article-title":"GluN2A and GluN2B N-methyl-D-aspartate receptor (NMDAR) subunits: their roles and therapeutic antagonists in neurological diseases","volume":"16","author":"Ladagu AD","year":"2023","unstructured":"Ladagu AD, Olopade FE, Adejare A, Olopade JO. GluN2A and GluN2B N-methyl-D-aspartate receptor (NMDAR) subunits: their roles and therapeutic antagonists in neurological diseases. Pharmaceuticals (Basel). 2023, 16:64-6. 10.3390\/ph16111535","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184391","article-title":"Roles of glutamate receptors in Parkinson's disease","volume":"20","author":"Zhang Z","year":"2019","unstructured":"Zhang Z, Zhang S, Fu P, Zhang Z, Lin K, Ko JK, Yung KK. Roles of glutamate receptors in Parkinson's disease. Int J Mol Sci. 2019, 20:51-3. 10.3390\/ijms20184391","journal-title":"Int J Mol Sci"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000050","article-title":"Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial","volume":"82","author":"Ory-Magne F","year":"2014","unstructured":"Ory-Magne F, Corvol JC, Azulay JP, et al.. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology. 2014, 82:300-7. 10.1212\/WNL.0000000000000050","journal-title":"Neurology"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26159","article-title":"Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)","volume":"30","author":"Pahwa R","year":"2015","unstructured":"Pahwa R, Tanner CM, Hauser RA, et al.. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study). Mov Disord. 2015, 30:788-95. 10.1002\/mds.26159","journal-title":"Mov Disord"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0498-4","article-title":"Pooled analyses of phase III studies of ADS-5102 (amantadine) extended-release capsules for dyskinesia in Parkinson's disease","volume":"32","author":"Elmer LW","year":"2018","unstructured":"Elmer LW, Juncos JL, Singer C, et al.. Pooled analyses of phase III studies of ADS-5102 (amantadine) extended-release capsules for dyskinesia in Parkinson's disease. CNS Drugs. 2018, 32:387-98. 10.1007\/s40263-018-0498-4","journal-title":"CNS Drugs"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27488","article-title":"Pimavanserin for Parkinson's disease psychosis: effects stratified by baseline cognition and use of cognitive-enhancing medications","volume":"33","author":"Espay AJ","year":"2018","unstructured":"Espay AJ, Guskey MT, Norton JC, et al.. Pimavanserin for Parkinson's disease psychosis: effects stratified by baseline cognition and use of cognitive-enhancing medications. Mov Disord. 2018, 33:1769-76. 10.1002\/mds.27488","journal-title":"Mov Disord"},{"key":"ref104","article-title":"Pimavanserin","author":"Cusick E","year":"2024","unstructured":"Cusick E, Gupta V. Pimavanserin. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings J","year":"2014","unstructured":"Cummings J, Isaacson S, Mills R, et al.. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014, 383:533-40. 10.1016\/S0140-6736(13)62106-6","journal-title":"Lancet"},{"key":"ref106","article-title":"Rivastigmine","author":"Patel PH","year":"2024","unstructured":"Patel PH, Gupta V. Rivastigmine. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S129145","article-title":"Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia","volume":"12","author":"Kandiah N","year":"2017","unstructured":"Kandiah N, Pai MC, Senanarong V, et al.. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia. Clin Interv Aging. 2017, 12:697-707. 10.2147\/CIA.S129145","journal-title":"Clin Interv Aging"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00389-0","article-title":"Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"15","author":"Henderson EJ","year":"2016","unstructured":"Henderson EJ, Lord SR, Brodie MA, et al.. Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016, 15:249-58. 10.1016\/S1474-4422(15)00389-0","journal-title":"Lancet Neurol"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1007\/s11302-020-09694-2","article-title":"The belated US FDA approval of the adenosine A(2A) receptor antagonist istradefylline for treatment of Parkinson's disease","volume":"16","author":"Chen JF","year":"2020","unstructured":"Chen JF, Cunha RA. The belated US FDA approval of the adenosine A(2A) receptor antagonist istradefylline for treatment of Parkinson's disease. Purinergic Signal. 2020, 16:167-74. 10.1007\/s11302-020-09694-2","journal-title":"Purinergic Signal"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-801022-8.00003-9","article-title":"An overview of adenosine A2A receptor antagonists in Parkinson's disease","volume":"119","author":"Jenner P","year":"2014","unstructured":"Jenner P. An overview of adenosine A2A receptor antagonists in Parkinson's disease. Int Rev Neurobiol. 2014, 119:71-86. 10.1016\/B978-0-12-801022-8.00003-9","journal-title":"Int Rev Neurobiol"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-18339-1","article-title":"The effect of istradefylline for Parkinson's disease: a meta-analysis","volume":"7","author":"Sako W","year":"2017","unstructured":"Sako W, Murakami N, Motohama K, Izumi Y, Kaji R. The effect of istradefylline for Parkinson's disease: a meta-analysis. Sci Rep. 2017, 7:18018. 10.1038\/s41598-017-18339-1","journal-title":"Sci Rep"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13160","article-title":"Clinical efficacy of istradefylline on lower urinary tract symptoms in Parkinson's disease","volume":"23","author":"Kitta T","year":"2016","unstructured":"Kitta T, Yabe I, Takahashi I, Matsushima M, Sasaki H, Shinohara N. Clinical efficacy of istradefylline on lower urinary tract symptoms in Parkinson's disease. Int J Urol. 2016, 23:893-4. 10.1111\/iju.13160","journal-title":"Int J Urol"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1614167","article-title":"Efficacy of istradefylline for gait disorders with freezing of gait in Parkinson's disease: a single-arm, open-label, prospective, multicenter study","volume":"20","author":"Iijima M","year":"2019","unstructured":"Iijima M, Orimo S, Terashi H, et al.. Efficacy of istradefylline for gait disorders with freezing of gait in Parkinson's disease: a single-arm, open-label, prospective, multicenter study. Expert Opin Pharmacother. 2019, 20:1405-11. 10.1080\/14656566.2019.1614167","journal-title":"Expert Opin Pharmacother"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1046\/j.0022-3042.2001.00694.x","article-title":"Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease","volume":"80","author":"Ikeda K","year":"2002","unstructured":"Ikeda K, Kurokawa M, Aoyama S, Kuwana Y. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease. J Neurochem. 2002, 80:262-70. 10.1046\/j.0022-3042.2001.00694.x","journal-title":"J Neurochem"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2020.10.024","article-title":"Do caffeine and more selective adenosine A(2A) receptor antagonists protect against dopaminergic neurodegeneration in Parkinson's disease?","volume":"80","author":"Chen JF","year":"2020","unstructured":"Chen JF, Schwarzschild MA. Do caffeine and more selective adenosine A(2A) receptor antagonists protect against dopaminergic neurodegeneration in Parkinson's disease?. Parkinsonism Relat Disord. 2020, 80:S45-53. 10.1016\/j.parkreldis.2020.10.024","journal-title":"Parkinsonism Relat Disord"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy147","article-title":"Is Parkinson's disease a lysosomal disorder?","volume":"141","author":"Klein AD","year":"2018","unstructured":"Klein AD, Mazzulli JR. Is Parkinson's disease a lysosomal disorder?. Brain. 2018, 141:2255-62. 10.1093\/brain\/awy147","journal-title":"Brain"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1920-10.2010","article-title":"Pathogenic lysosomal depletion in Parkinson's disease","volume":"30","author":"Dehay B","year":"2010","unstructured":"Dehay B, Bov\u00e9 J, Rodr\u00edguez-Muela N, Perier C, Recasens A, Boya P, Vila M. Pathogenic lysosomal depletion in Parkinson's disease. J Neurosci. 2010, 30:12535-44. 10.1523\/JNEUROSCI.1920-10.2010","journal-title":"J Neurosci"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.4161\/auto.21447","article-title":"Lysosomal dysfunction in Parkinson disease: ATP13A2 gets into the groove","volume":"8","author":"Tofaris GK","year":"2012","unstructured":"Tofaris GK, Layfield R, O'Kane CJ. Lysosomal dysfunction in Parkinson disease: ATP13A2 gets into the groove. Autophagy. 2012, 8:1383-4. 10.4161\/auto.21447","journal-title":"Autophagy"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510137","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease","volume":"374","author":"Sidransky E","year":"2016","unstructured":"Sidransky E, Nalls MA, Aasly JO, et al.. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2016, 374:2041-53. 10.1056\/NEJMoa1510137","journal-title":"N Engl J Med"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awu020","article-title":"Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells","volume":"137","author":"McNeill A","year":"2014","unstructured":"McNeill A, Magalhaes J, Shen C, et al.. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain. 2014, 137:1481-95. 10.1093\/brain\/awu020","journal-title":"Brain"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.4606","article-title":"Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations","volume":"77","author":"Mullin S","year":"2020","unstructured":"Mullin S, Smith L, Lee K, et al.. Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations. JAMA Neurol. 2020, 77:427-34. 10.1001\/jamaneurol.2019.4606","journal-title":"JAMA Neurol"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2023-000535","article-title":"Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in GBA-associated Parkinson's disease: a multicentre, randomised, double-blind, placebo-controlled, phase II trial. The AMBITIOUS study protocol","volume":"5","author":"Colucci F","year":"2023","unstructured":"Colucci F, Avenali M, De Micco R, et al.. Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in GBA-associated Parkinson's disease: a multicentre, randomised, double-blind, placebo-controlled, phase II trial. The AMBITIOUS study protocol. BMJ Neurol Open. 2023, 5:e000535. 10.1136\/bmjno-2023-000535","journal-title":"BMJ Neurol Open"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.84","article-title":"Buntanetap, a novel translational inhibitor of multiple neurotoxic proteins, proves to be safe and promising in both Alzheimer's and Parkinson's patients","volume":"10","author":"Fang C","year":"2023","unstructured":"Fang C, Hernandez P, Liow K, et al.. Buntanetap, a novel translational inhibitor of multiple neurotoxic proteins, proves to be safe and promising in both Alzheimer's and Parkinson's patients. J Prev Alzheimers Dis. 2023, 10:25-33. 10.14283\/jpad.2022.84","journal-title":"J Prev Alzheimers Dis"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073812","article-title":"GLP-1 receptor agonists: a new treatment in Parkinson's disease","volume":"25","author":"Kalinderi K","year":"2024","unstructured":"Kalinderi K, Papaliagkas V, Fidani L. GLP-1 receptor agonists: a new treatment in Parkinson's disease. Int J Mol Sci. 2024, 25:32-4. 10.3390\/ijms25073812","journal-title":"Int J Mol Sci"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.78575","article-title":"A system-based review on effects of glucagon-like peptide-1 receptor agonists: benefits vs risks","volume":"17","author":"Fadel LP","year":"2025","unstructured":"Fadel LP, Thao G, Chitre T, et al.. A system-based review on effects of glucagon-like peptide-1 receptor agonists: benefits vs risks. Cureus. 2025, 17:e78575. 10.7759\/cureus.78575","journal-title":"Cureus"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao X","year":"2021","unstructured":"Zhao X, Wang M, Wen Z, et al.. GLP-1 receptor agonists: beyond their pancreatic effects. Front Endocrinol (Lausanne). 2021, 12:721135. 10.3389\/fendo.2021.721135","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-047993","article-title":"Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo-controlled, phase 3 trial: the 'Exenatide-PD3' study","volume":"11","author":"Vijiaratnam N","year":"2021","unstructured":"Vijiaratnam N, Girges C, Auld G, et al.. Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo-controlled, phase 3 trial: the 'Exenatide-PD3' study. BMJ Open. 2021, 11:e047993. 10.1136\/bmjopen-2020-047993","journal-title":"BMJ Open"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2015.04.010","article-title":"Exenatide protects dopaminergic neurons in a mouse model of Parkinson's disease","volume":"97","author":"Wang Y","year":"2015","unstructured":"Wang Y, Zhang L, Zhang Y, et al.. Exenatide protects dopaminergic neurons in a mouse model of Parkinson's disease. Neuropharmacology. 2015, 97:1-9. 10.1016\/j.neuropharm.2015.04.010","journal-title":"Neuropharmacology"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse JB","year":"2004","unstructured":"Buse JB, Henry RR, Han J, et al.. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004, 27:2628-35. 10.2337\/diacare.27.11.2628","journal-title":"Diabetes Care"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0806720106","article-title":"GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism","volume":"106","author":"Li Y","year":"2009","unstructured":"Li Y, Perry T, Kindy MS, et al.. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A. 2009, 106:1285-90. 10.1073\/pnas.0806720106","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31601-1","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda DH","year":"2017","unstructured":"Athauda DH, Maclagan K, O'Sullivan SS, et al.. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017, 390:1664-75. 10.1016\/S0140-6736(17)31601-1","journal-title":"Lancet"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa287","article-title":"Diabetes medications and risk of Parkinson's disease: a cohort study","volume":"143","author":"Brauer R","year":"2020","unstructured":"Brauer R, Jick SS, Meier CR, Jick H. Diabetes medications and risk of Parkinson's disease: a cohort study. Brain. 2020, 143:2868-71. 10.1093\/brain\/awaa287","journal-title":"Brain"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.98.18_supplement.3068","article-title":"Liraglutide improves non-motor function and activities of daily living in patients with Parkinson's disease: a randomized, double-blind, placebo-controlled trial","volume":"98","author":"Malatt C","year":"2022","unstructured":"Malatt C, Wu T, Bresee C, et al.. Liraglutide improves non-motor function and activities of daily living in patients with Parkinson's disease: a randomized, double-blind, placebo-controlled trial. Neurology. 2022, 98:9-11. 10.1212\/WNL.98.18_supplement.3068","journal-title":"Neurology"},{"key":"ref134","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-022-00295-x","article-title":"Gastrointestinal involvement in Parkinson's disease: pathophysiology, diagnosis, and management","volume":"8","author":"Warnecke T","year":"2022","unstructured":"Warnecke T, Sch\u00e4fer KH, Claus I, Del Tredici K, Jost WH. Gastrointestinal involvement in Parkinson's disease: pathophysiology, diagnosis, and management. NPJ Parkinsons Dis. 2022, 8:31. 10.1038\/s41531-022-00295-x","journal-title":"NPJ Parkinsons Dis"},{"key":"ref135","doi-asserted-by":"publisher","DOI":"10.14802\/jmd.22220","article-title":"Gastrointestinal dysfunction in Parkinson's disease: neuro-gastroenterology perspectives on a multifaceted problem","volume":"16","author":"Tan AH","year":"2023","unstructured":"Tan AH, Chuah KH, Beh YY, Schee JP, Mahadeva S, Lim SY. Gastrointestinal dysfunction in Parkinson's disease: neuro-gastroenterology perspectives on a multifaceted problem. J Mov Disord. 2023, 16:138-51. 10.14802\/jmd.22220","journal-title":"J Mov Disord"},{"key":"ref136","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2018.05.018","article-title":"Clinical and metabolic response to probiotic administration in people with Parkinson's disease: a randomized, double-blind, placebo-controlled trial","volume":"38","author":"Tamtaji OR","year":"2019","unstructured":"Tamtaji OR, Taghizadeh M, Daneshvar Kakhaki R, et al.. Clinical and metabolic response to probiotic administration in people with Parkinson's disease: a randomized, double-blind, placebo-controlled trial. Clin Nutr. 2019, 38:1031-5. 10.1016\/j.clnu.2018.05.018","journal-title":"Clin Nutr"},{"key":"ref137","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010998","article-title":"Probiotics for constipation in Parkinson disease: a randomized placebo-controlled study","volume":"96","author":"Tan AH","year":"2021","unstructured":"Tan AH, Lim SY, Chong KK, et al.. Probiotics for constipation in Parkinson disease: a randomized placebo-controlled study. Neurology. 2021, 96:772-82. 10.1212\/WNL.0000000000010998","journal-title":"Neurology"},{"key":"ref138","unstructured":"Role and mechanism of probiotics in improving motor symptoms in mild to moderate Parkinson's disease. (2025). Accessed. April 19, 2025: https:\/\/clinicaltrials.gov\/study\/NCT05576818."},{"key":"ref139","unstructured":"Effect of Bifidobacterium triple viable capsules in patients with Parkinson's disease. (2025). Accessed. April 19, 2025: https:\/\/clinicaltrials.gov\/study\/NCT04871464."},{"key":"ref140","doi-asserted-by":"publisher","DOI":"10.2174\/1871527322666230331121028","article-title":"Rationale and development of tavapadon, a D1\/D5-selective partial dopamine agonist for the treatment of Parkinson's disease","volume":"23","author":"Bezard E","year":"2024","unstructured":"Bezard E, Gray D, Kozak R, Leoni M, Combs C, Duvvuri S. Rationale and development of tavapadon, a D1\/D5-selective partial dopamine agonist for the treatment of Parkinson's disease. CNS Neurol Disord Drug Targets. 2024, 23:476-87. 10.2174\/1871527322666230331121028","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref141","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-018-0114-z","article-title":"Phase 1 Parkinson's disease studies show the dopamine D1\/D5 agonist PF-06649751 is safe and well tolerated","volume":"7","author":"Sohur US","year":"2018","unstructured":"Sohur US, Gray DL, Duvvuri S, Zhang Y, Thayer K, Feng G. Phase 1 Parkinson's disease studies show the dopamine D1\/D5 agonist PF-06649751 is safe and well tolerated. Neurol Ther. 2018, 7:307-19. 10.1007\/s40120-018-0114-z","journal-title":"Neurol Ther"},{"key":"ref142","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420911296","article-title":"PF-06649751 efficacy and safety in early Parkinson's disease: a randomized, placebo-controlled trial","volume":"13","author":"Riesenberg R","year":"2020","unstructured":"Riesenberg R, Werth J, Zhang Y, Duvvuri S, Gray D. PF-06649751 efficacy and safety in early Parkinson's disease: a randomized, placebo-controlled trial. Ther Adv Neurol Disord. 2020, 13:1756286420911296. 10.1177\/1756286420911296","journal-title":"Ther Adv Neurol Disord"},{"key":"ref143","unstructured":"Open-label trial in Parkinson's disease (PD) (TEMPO-4). (2025). Accessed. April 19, 2025: https:\/\/clinicaltrials.gov\/study\/NCT04760769."},{"key":"ref144","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-202285","article-title":"Continuous subcutaneous levodopa delivery for Parkinson's disease: a randomized study","volume":"11","author":"Olanow CW","year":"2021","unstructured":"Olanow CW, Espay AJ, Stocchi F, et al.. Continuous subcutaneous levodopa delivery for Parkinson's disease: a randomized study. J Parkinsons Dis. 2021, 11:177-86. 10.3233\/JPD-202285","journal-title":"J Parkinsons Dis"},{"key":"ref145","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2021.09.024","article-title":"ND0612 (levodopa\/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: a randomized, placebo-controlled phase 2 study","volume":"91","author":"Giladi N","year":"2021","unstructured":"Giladi N, Gurevich T, Djaldetti R, et al.. ND0612 (levodopa\/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: a randomized, placebo-controlled phase 2 study. Parkinsonism Relat Disord. 2021, 91:139-45. 10.1016\/j.parkreldis.2021.09.024","journal-title":"Parkinsonism Relat Disord"},{"key":"ref146","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1036068","article-title":"The pharmacokinetics of continuous subcutaneous levodopa\/carbidopa infusion: findings from the ND0612 clinical development program","volume":"13","author":"LeWitt PA","year":"2022","unstructured":"LeWitt PA, Stocchi F, Arkadir D, et al.. The pharmacokinetics of continuous subcutaneous levodopa\/carbidopa infusion: findings from the ND0612 clinical development program. Front Neurol. 2022, 13:1036068. 10.3389\/fneur.2022.1036068","journal-title":"Front Neurol"},{"key":"ref147","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28758","article-title":"Subcutaneous levodopa infusion for Parkinson's disease: 1-year data from the open-label BeyoND study","volume":"36","author":"Poewe W","year":"2021","unstructured":"Poewe W, Stocchi F, Arkadir D, et al.. Subcutaneous levodopa infusion for Parkinson's disease: 1-year data from the open-label BeyoND study. Mov Disord. 2021, 36:2687-92. 10.1002\/mds.28758","journal-title":"Mov Disord"},{"key":"ref148","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-023-02686-7","article-title":"Practical use of apomorphine infusion in Parkinson's disease: lessons from the TOLEDO study and clinical experience","volume":"130","author":"Henriksen T","year":"2023","unstructured":"Henriksen T, Katzenschlager R, Bhidayasiri R, Staines H, Lockhart D, Lees A. Practical use of apomorphine infusion in Parkinson's disease: lessons from the TOLEDO study and clinical experience. J Neural Transm (Vienna). 2023, 130:1475-84. 10.1007\/s00702-023-02686-7","journal-title":"J Neural Transm (Vienna)"},{"key":"ref149","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2020.12.024","article-title":"Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: results of the open-label phase of the TOLEDO study","volume":"83","author":"Katzenschlager R","year":"2021","unstructured":"Katzenschlager R, Poewe W, Rascol O, et al.. Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: results of the open-label phase of the TOLEDO study. Parkinsonism Relat Disord. 2021, 83:79-85. 10.1016\/j.parkreldis.2020.12.024","journal-title":"Parkinsonism Relat Disord"},{"key":"ref150","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-230072","article-title":"Apomorphine sublingual film compared with subcutaneous apomorphine for OFF episodes in Parkinson's disease: an open-label, randomized, crossover study","volume":"13","author":"Stocchi F","year":"2023","unstructured":"Stocchi F, Rascol O, Poewe W, et al.. Apomorphine sublingual film compared with subcutaneous apomorphine for OFF episodes in Parkinson's disease: an open-label, randomized, crossover study. J Parkinsons Dis. 2023, 13:1329-42. 10.3233\/JPD-230072","journal-title":"J Parkinsons Dis"},{"key":"ref151","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-223537","article-title":"Dose optimization of apomorphine sublingual film for OFF episodes in Parkinson's disease: is the prophylactic use of an antiemetic necessary?","volume":"13","author":"Hauser RA","year":"2023","unstructured":"Hauser RA, Ondo WG, Zhang Y, Bowling A, Navia B, Pappert E, Isaacson SH. Dose optimization of apomorphine sublingual film for OFF episodes in Parkinson's disease: is the prophylactic use of an antiemetic necessary?. J Parkinsons Dis. 2023, 13:403-14. 10.3233\/JPD-223537","journal-title":"J Parkinsons Dis"},{"key":"ref152","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26073","article-title":"Foslevodopa\/foscarbidopa: a new subcutaneous treatment for Parkinson's disease","volume":"90","author":"Rosebraugh M","year":"2021","unstructured":"Rosebraugh M, Voight EA, Moussa EM, et al.. Foslevodopa\/foscarbidopa: a new subcutaneous treatment for Parkinson's disease. Ann Neurol. 2021, 90:52-61. 10.1002\/ana.26073","journal-title":"Ann Neurol"},{"key":"ref153","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00400-8","article-title":"Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomized, double-blind, active-controlled, phase 3 trial","volume":"21","author":"Soileau MJ","year":"2022","unstructured":"Soileau MJ, Aldred J, Budur K, et al.. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomized, double-blind, active-controlled, phase 3 trial. Lancet Neurol. 2022, 21:1099-109. 10.1016\/S1474-4422(22)00400-8","journal-title":"Lancet Neurol"},{"key":"ref154","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02097-2","article-title":"P2B001 (extended-release pramipexole and rasagiline): a new treatment option in development for Parkinson's disease","volume":"39","author":"Hauser RA","year":"2022","unstructured":"Hauser RA, Giladi N, Poewe W, Brotchie J, Friedman H, Oren S, Litman P. P2B001 (extended-release pramipexole and rasagiline): a new treatment option in development for Parkinson's disease. Adv Ther. 2022, 39:1881-94. 10.1007\/s12325-022-02097-2","journal-title":"Adv Ther"},{"key":"ref155","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29642","article-title":"A randomized phase 3 study comparing P2B001 to its components (low-dose extended-release rasagiline and pramipexole) and to optimized doses of marketed extended-release pramipexole in early Parkinson's disease","volume":"39","author":"Olanow CW","year":"2024","unstructured":"Olanow CW, Hauser RA, Burdick DJ, et al.. A randomized phase 3 study comparing P2B001 to its components (low-dose extended-release rasagiline and pramipexole) and to optimized doses of marketed extended-release pramipexole in early Parkinson's disease. Mov Disord. 2024, 39:350-9. 10.1002\/mds.29642","journal-title":"Mov Disord"},{"key":"ref156","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00330-6","article-title":"The neuropsychiatry of Parkinson's disease: advances and challenges","volume":"21","author":"Weintraub D","year":"2022","unstructured":"Weintraub D, Aarsland D, Chaudhuri KR, Dobkin RD, Leentjens AF, Rodriguez-Violante M, Schrag A. The neuropsychiatry of Parkinson's disease: advances and challenges. Lancet Neurol. 2022, 21:89-102. 10.1016\/S1474-4422(21)00330-6","journal-title":"Lancet Neurol"},{"key":"ref157","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-022-02988-5","article-title":"Antidepressants Trial in Parkinson's Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson's disease","volume":"22","author":"Schrag A","year":"2022","unstructured":"Schrag A, Carroll C, Duncan G, et al.. Antidepressants Trial in Parkinson's Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson's disease. BMC Neurol. 2022, 22:474. 10.1186\/s12883-022-02988-5","journal-title":"BMC Neurol"},{"key":"ref158","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2015\/11394.5583","article-title":"A case of SSRI-induced irreversible parkinsonism","volume":"9","author":"Dixit S","year":"2015","unstructured":"Dixit S, Khan SA, Azad S. A case of SSRI-induced irreversible parkinsonism. J Clin Diagn Res. 2015, 9:VD01-2. 10.7860\/JCDR\/2015\/11394.5583","journal-title":"J Clin Diagn Res"},{"key":"ref159","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2017.07.007","article-title":"Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form","volume":"106","author":"Collier TJ","year":"2017","unstructured":"Collier TJ, Srivastava KR, Justman C, et al.. Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form. Neurobiol Dis. 2017, 106:191-204. 10.1016\/j.nbd.2017.07.007","journal-title":"Neurobiol Dis"},{"key":"ref160","doi-asserted-by":"publisher","DOI":"10.1126\/science.1195227","article-title":"Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro","volume":"329","author":"Burr\u00e9 J","year":"2010","unstructured":"Burr\u00e9 J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, S\u00fcdhof TC. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science. 2010, 329:1663-7. 10.1126\/science.1195227","journal-title":"Science"},{"key":"ref161","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-013-1073-5","article-title":"The neurobiology of LRRK2 and its role in the pathogenesis of Parkinson's disease","volume":"39","author":"Rideout HJ","year":"2014","unstructured":"Rideout HJ, Stefanis L. The neurobiology of LRRK2 and its role in the pathogenesis of Parkinson's disease. Neurochem Res. 2014, 39:576-92. 10.1007\/s11064-013-1073-5","journal-title":"Neurochem Res"},{"key":"ref162","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2011.06.001","article-title":"VPS35 mutations in Parkinson disease","volume":"89","author":"Vilari\u00f1o-G\u00fcell C","year":"2011","unstructured":"Vilari\u00f1o-G\u00fcell C, Wider C, Ross OA, et al.. VPS35 mutations in Parkinson disease. Am J Hum Genet. 2011, 89:162-7. 10.1016\/j.ajhg.2011.06.001","journal-title":"Am J Hum Genet"},{"key":"ref163","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-020-00367-7","article-title":"PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson's disease","volume":"15","author":"Ge P","year":"2020","unstructured":"Ge P, Dawson VL, Dawson TM. PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson's disease. Mol Neurodegener. 2020, 15:20. 10.1186\/s13024-020-00367-7","journal-title":"Mol Neurodegener"},{"key":"ref164","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200910140","article-title":"PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy","volume":"189","author":"Matsuda N","year":"2010","unstructured":"Matsuda N, Sato S, Shiba K, et al.. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J Cell Biol. 2010, 189:211-21. 10.1083\/jcb.200910140","journal-title":"J Cell Biol"},{"key":"ref165","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/683920","article-title":"Neuroprotective function of DJ-1 in Parkinson's disease","volume":"2013","author":"Ariga H","year":"2013","unstructured":"Ariga H, Takahashi-Niki K, Kato I, Maita H, Niki T, Iguchi-Ariga SM. Neuroprotective function of DJ-1 in Parkinson's disease. Oxid Med Cell Longev. 2013, 2013:683920. 10.1155\/2013\/683920","journal-title":"Oxid Med Cell Longev"},{"key":"ref166","doi-asserted-by":"publisher","DOI":"10.1038\/ng1884","article-title":"Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase","volume":"38","author":"Ramirez A","year":"2006","unstructured":"Ramirez A, Heimbach A, Gr\u00fcndemann J, et al.. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet. 2006, 38:1184-91. 10.1038\/ng1884","journal-title":"Nat Genet"},{"key":"ref167","doi-asserted-by":"publisher","DOI":"10.15586\/codonpublications.parkinsonsdisease.2018.ch7","article-title":"Pharmacological treatment of Parkinson\u2019s disease","author":"Zahoor I","year":"2018","unstructured":"Zahoor I, Shafi A, Haq E. Pharmacological treatment of Parkinson\u2019s disease. Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects. Stoker TB, Greenland JC (ed): Codon Publications, Brisbane, Australia; 2018. 4:32-4. 10.15586\/codonpublications.parkinsonsdisease.2018.ch7"},{"key":"ref168","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2004.10.023","article-title":"Cloning of the gene containing mutations that cause PARK8-linked Parkinson\u2019s disease","volume":"44","author":"Pais\u00e1n-Ru\u00edz C","year":"2004","unstructured":"Pais\u00e1n-Ru\u00edz C, Jain S, Evans EW, et al.. Cloning of the gene containing mutations that cause PARK8-linked Parkinson\u2019s disease. Neuron. 2004, 44:595-600. 10.1016\/j.neuron.2004.10.023","journal-title":"Neuron"},{"key":"ref169","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2004.11.005","article-title":"Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology","volume":"44","author":"Zimprich A","year":"2004","unstructured":"Zimprich A, Biskup S, Leitner P, et al.. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004, 44:601-7. 10.1016\/j.neuron.2004.11.005","journal-title":"Neuron"},{"key":"ref170","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29297","article-title":"LRRK2 inhibition by BIIB122 in healthy participants and patients with Parkinson's disease","volume":"38","author":"Jennings D","year":"2023","unstructured":"Jennings D, Huntwork-Rodriguez S, Vissers MFJM, et al.. LRRK2 inhibition by BIIB122 in healthy participants and patients with Parkinson's disease. Mov Disord. 2023, 38:386-98. 10.1002\/mds.29297","journal-title":"Mov Disord"},{"key":"ref171","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-023-00544-7","article-title":"Perspective on the current state of the LRRK2 field","volume":"9","author":"Taymans JM","year":"2023","unstructured":"Taymans JM, Fell M, Greenamyre T, et al.. Perspective on the current state of the LRRK2 field. NPJ Parkinsons Dis. 2023, 9:104. 10.1038\/s41531-023-00544-7","journal-title":"NPJ Parkinsons Dis"},{"key":"ref172","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-020-0117-1","article-title":"Current and projected future economic burden of Parkinson's disease in the U.S","volume":"6","author":"Yang W","year":"2020","unstructured":"Yang W, Hamilton JL, Kopil C, et al.. Current and projected future economic burden of Parkinson's disease in the U.S. NPJ Parkinsons Dis. 2020, 6:15. 10.1038\/s41531-020-0117-1","journal-title":"NPJ Parkinsons Dis"},{"key":"ref173","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2020.113234","article-title":"Pioglitazone activates paraoxonase-2 in the brain: a novel neuroprotective mechanism","volume":"327","author":"Blackburn JK","year":"2020","unstructured":"Blackburn JK, Curry DW, Thomsen AN, Roth RH, Elsworth JD. Pioglitazone activates paraoxonase-2 in the brain: a novel neuroprotective mechanism. Exp Neurol. 2020, 327:113234. 10.1016\/j.expneurol.2020.113234","journal-title":"Exp Neurol"},{"key":"ref174","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104671","article-title":"Modifiable risk and protective factors in disease development, progression and clinical subtypes of Parkinson's disease: What do prospective studies suggest?","volume":"134","author":"Belvisi D","year":"2020","unstructured":"Belvisi D, Pellicciari R, Fabbrini G, Tinazzi M, Berardelli A, Defazio G. Modifiable risk and protective factors in disease development, progression and clinical subtypes of Parkinson's disease: What do prospective studies suggest?. Neurobiol Dis. 2020, 134:104671. 10.1016\/j.nbd.2019.104671","journal-title":"Neurobiol Dis"},{"key":"ref175","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.07.022","article-title":"Parkinson's disease: autoimmunity and neuroinflammation","volume":"15","author":"De Virgilio A","year":"2016","unstructured":"De Virgilio A, Greco A, Fabbrini G, et al.. Parkinson's disease: autoimmunity and neuroinflammation. Autoimmun Rev. 2016, 15:1005-11. 10.1016\/j.autrev.2016.07.022","journal-title":"Autoimmun Rev"},{"key":"ref176","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.5314-13.2014","article-title":"Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models","volume":"34","author":"Games D","year":"2014","unstructured":"Games D, Valera E, Spencer B, et al.. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models. J Neurosci. 2014, 34:9441-54. 10.1523\/JNEUROSCI.5314-13.2014","journal-title":"J Neurosci"},{"key":"ref177","doi-asserted-by":"publisher","DOI":"10.1002\/biof.20","article-title":"Insulin-like growth factor-I receptor signal transduction and the Janus kinase\/signal transducer and activator of transcription (JAK-STAT) pathway","volume":"35","author":"Himpe E","year":"2009","unstructured":"Himpe E, Kooijman R. Insulin-like growth factor-I receptor signal transduction and the Janus kinase\/signal transducer and activator of transcription (JAK-STAT) pathway. Biofactors. 2009, 35:76-81. 10.1002\/biof.20","journal-title":"Biofactors"},{"key":"ref178","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1720621","article-title":"Alpha-synuclein in Parkinson's disease: from pathogenetic dysfunction to potential clinical application","volume":"2016","author":"Xu L","year":"2016","unstructured":"Xu L, Pu J. Alpha-synuclein in Parkinson's disease: from pathogenetic dysfunction to potential clinical application. Parkinsons Dis. 2016, 2016:1720621. 10.1155\/2016\/1720621","journal-title":"Parkinsons Dis"},{"key":"ref179","doi-asserted-by":"publisher","DOI":"10.1038\/nrn3406","article-title":"The many faces of \u03b1-synuclein: from structure and toxicity to therapeutic target","volume":"14","author":"Lashuel HA","year":"2013","unstructured":"Lashuel HA, Overk CR, Oueslati A, Masliah E. The many faces of \u03b1-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci. 2013, 14:38-48. 10.1038\/nrn3406","journal-title":"Nat Rev Neurosci"},{"key":"ref180","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4593","article-title":"Targeting protein aggregation for the treatment of degenerative diseases","volume":"14","author":"Eisele YS","year":"2015","unstructured":"Eisele YS, Monteiro C, Fearns C, Encalada SE, Wiseman RL, Powers ET, Kelly JW. Targeting protein aggregation for the treatment of degenerative diseases. Nat Rev Drug Discov. 2015, 14:759-80. 10.1038\/nrd4593","journal-title":"Nat Rev Drug Discov"},{"key":"ref181","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1610586114","article-title":"A natural product inhibits the initiation of \u03b1-synuclein aggregation and suppresses its toxicity","volume":"114","author":"Perni M","year":"2017","unstructured":"Perni M, Galvagnion C, Maltsev A, et al.. A natural product inhibits the initiation of \u03b1-synuclein aggregation and suppresses its toxicity. Proc Natl Acad Sci U S A. 2017, 114:E1009-17. 10.1073\/pnas.1610586114","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref182","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1616892114","article-title":"Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease","volume":"114","author":"Dunn AR","year":"2017","unstructured":"Dunn AR, Stout KA, Ozawa M, et al.. Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease. Proc Natl Acad Sci U S A. 2017, 114:E2253-62. 10.1073\/pnas.1616892114","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref183","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-171191","article-title":"c-Abl and Parkinson's disease: mechanisms and therapeutic potential","volume":"7","author":"Brahmachari S","year":"2017","unstructured":"Brahmachari S, Karuppagounder SS, Ge P, Lee S, Dawson VL, Dawson TM, Ko HS. c-Abl and Parkinson's disease: mechanisms and therapeutic potential. J Parkinsons Dis. 2017, 7:589-601. 10.3233\/JPD-171191","journal-title":"J Parkinsons Dis"},{"key":"ref184","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000597","article-title":"Abelson tyrosine kinase inhibitors in Parkinson's disease and Lewy body dementia: a systematic review, meta-analysis, and meta-regression","volume":"47","author":"Gosch Berton G","year":"2024","unstructured":"Gosch Berton G, Cyntia Lima Fonseca Rodrigues A, Dos Santos Borges R, Rodrigues Cardoso N, de Oliveira TA, Oliveira Marques MV. Abelson tyrosine kinase inhibitors in Parkinson's disease and Lewy body dementia: a systematic review, meta-analysis, and meta-regression. Clin Neuropharmacol. 2024, 47:113-9. 10.1097\/WNF.0000000000000597","journal-title":"Clin Neuropharmacol"},{"key":"ref185","article-title":"Dopaminergic neuronal cell therapy for Parkinson\u2019s disease: results from a phase 1 study of bemdaneprocel","volume":"38","author":"Henchcliffe C","year":"2023","unstructured":"Henchcliffe C, Sarva H, Lozano A, et al.. Dopaminergic neuronal cell therapy for Parkinson\u2019s disease: results from a phase 1 study of bemdaneprocel. Mov Disord. 2023, 38:17-9.","journal-title":"Mov Disord"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/363706-a-review-of-the-recent-advances-in-the-pharmacological-management-of-parkinsons-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T16:43:04Z","timestamp":1758732184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/363706-a-review-of-the-recent-advances-in-the-pharmacological-management-of-parkinsons-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":185,"URL":"https:\/\/doi.org\/10.7759\/cureus.93123","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,24]]}}}